The latest update is out from Thiogenesis Therapeutics Corp ( (TSE:TTI) ).
Thiogenesis Therapeutics Corp has received final clearance from the European Medicines Agency to commence a Phase 2 clinical trial for its lead compound TTI-0102, aimed at treating mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS). This multi-country, multi-center trial will be conducted in France and the Netherlands, involving 12 patients to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of TTI-0102 over six months. The trial’s success could position Thiogenesis as a leader in providing treatment solutions for MELAS, a rare and currently untreatable mitochondrial disorder, potentially impacting stakeholders by offering a new therapeutic avenue.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company focused on developing disulfides that enhance the production of key intracellular antioxidants and other therapeutic compounds.
YTD Price Performance: 7.56%
Average Trading Volume: 22,252
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$28.19M
See more data about TTI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com